Developer docs
API playgroundTry for free, no card

Search company profiles

Immcell Ltd

Full company profile

uuid02lwlzn

Namestring
Immcell Ltd
Legal namestring
Immcell Limited
Websiteurl
immcell.ie
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Immcell Limited is an Ireland-based, family-owned B2B ingredient and pharmaceutical technology company operating within the Immdal Group, headquartered in Swords, Co. Dublin. The company develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions through two operating divisions: Immcell Nutra, which supplies functional food ingredients such as Rapeseed Protein (a PDCAAS-1 plant protein derived from rapeseed meal, a by-product of cold press oil extraction) and B-NUC™ (a trademarked high-purity beta polymorph of inosine positioned for immune system modulation); and Immcell Pharma, which is developing a Natural Biofilm Inhibitor in collaboration with Technological University Dublin, targeting biofilm prevention and disruption across food manufacturing and healthcare applications.

The underlying technology relies on proprietary natural-compound formulations, GMP manufacturing standards, and academic co-development rather than in-house AI-driven discovery. Products are positioned for integration into B2B partners' own brands and formulations, with applications spanning nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, bakery, capsules, beverages, medical devices, and food preservation. Manufacturing is conducted to GMP standards and is accompanied by a consolidated clinical development network for the pharmaceutical product line.

Immcell monetizes primarily through B2B licensing and distribution agreements with food and pharmaceutical industry partners, complemented by direct R&D sample sales (for example, Rapeseed Protein priced at €30 per 10 grams) via an online shop to facilitate partner evaluation. Go-to-market is sales-led, conducted through the corporate website, newsletter, and direct contact (phone and email), with no consumer-facing retail channel. The company's stated target markets are global, although its identified served geography is currently EMEA, and no customer logos, revenue figures, or funding rounds are publicly disclosed.

Short descriptiontext

Immcell Limited is an Ireland-based, family-owned B2B company within the Immdal Group that develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions, including Rapeseed Protein, B-NUC™ Beta Inosine, and a Natural Biofilm Inhibitor, to food and pharmaceutical industry partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSwords, Ireland
HQ citystring
Swords
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
plant-based protein ingredients, functional food ingredients, nutraceutical ingredients, pharmaceutical technology licensing, anti-biofilm technology
Industry3 codes
PRIMARYCRADAOAM
Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYAFAKAJAD
Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium)
Agriculture & Food Production/Food Processing & Manufacturing/Specialty & Functional Foods Manufacturing (Organic, Fortified, Medical Foods)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Miscellaneous Food Preparations & Kindred Products2090
Product category
Plant-based Nutraceutical Ingredients
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1B2B Product Licensing
TypeLicensing Royalties
Description

Licensing innovative plant-based technologies and ingredients to B2B partners in the food and pharmaceutical industries for integration into their product formulations and brands.

immcell.ie
2Sample Product Sales
TypeOne Time License
Description

Direct sales of product samples (Rapeseed Protein at €30.00 for 10 grams) for R&D purposes to potential B2B partners evaluating ingredients for incorporation into their products.

immcell.ie
3Technology Solutions Licensing
TypeLicensing Royalties
Description

Licensing of pharmaceutical technology solutions including the Natural Biofilm Inhibitor technology to healthcare and pharmaceutical companies.

immcell.ie
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1Rapeseed Protein Sample (10g)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€30.00 per unit, 10 grams per unit, in stock. For R&D purposes only.

immcell.ie
2B-NUC™ (Beta Inosine) - Commercial Quantities
ModelOtherBilling cadenceMulti-year contract
Notes

Available on request for commercial B2B orders

immcell.ie
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1B-NUC™ (Beta Inosine)
Description

Innovative functional food ingredient - a high purity beta polymorph of inosine that modulates the immune system.

immcell.ie
+2 more records
Core offering1 text field

Immcell develops and supplies proprietary plant-based nutraceutical ingredients and pharmaceutical technology solutions to B2B customers in the food and pharmaceutical industries. Its commercial portfolio centers on Rapeseed Protein (a plant-based protein from rapeseed meal), B-NUC™ Beta Inosine (an immune-modulating functional ingredient), and the Natural Biofilm Inhibitor (anti-biofilm technology developed with Technological University Dublin), all manufactured to GMP standards and delivered primarily via licensing and ingredient supply partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Plant-based food sales grew 5 times faster than overall retail food sales (11% v 2%)
+2 more records
Product overview1 text field

Immcell operates through two main divisions: Immcell Nutra and Immcell Pharma. Immcell Nutra offers functional food ingredients including Rapeseed Protein (plant-based protein with complete amino acid profile for nutritional applications) and B-NUC™ (Beta Inosine), an immune-modulating functional ingredient. Immcell Pharma focuses on technology-based pharmaceutical solutions, including the Natural Biofilm Inhibitor developed in collaboration with Technological University Dublin. The company manufactures products to GMP standards for B2B distribution and licensing.

Product and service3 records
1Rapeseed Protein (RSP)
CategoryPlant-based functional food ingredients / Protein ingredients
Description

Plant-based protein ingredient produced from rapeseed meal (a by-product of cold press rapeseed oil extraction), with a complete essential amino acid profile, non-GMO and Irish-sourced credentials, dairy and lactose free, and a PDCAAS-1 rating. Designed for B2B integration into nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, and bakery products by food and beverage manufacturers.

2B-NUC™ (Beta Inosine)
CategoryPlant-based functional food ingredients / Immune-modulating ingredients
Description

Trademarked high-purity beta polymorph of inosine developed by Immcell as a functional food ingredient that modulates the immune system, supporting innate and adaptive immunity, cognition, energy generation, nerve cell and brain health, and heart health. Suitable for capsules, gels, bars, protein powders, yoghurts, beverages, and smoothies across all age groups, with particular relevance for the ageing population; offered for B2B licensing and supply.

3Natural Biofilm Inhibitor
CategoryPharmaceutical technology solutions / Anti-biofilm technology
Description

Anti-biofilm pharmaceutical technology developed with Technological University Dublin (TUD) that investigates anti-biofilm activity of specific compounds, targeting both prevention of biofilm formation and post-formation disruption. Intended for B2B licensing to medical device manufacturers (catheters, prosthetics), food and beverage manufacturing plants, and fruit and vegetable preservation applications in the pharmaceutical and healthcare sectors.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing research collaboration investigating anti-biofilm activity of specific compounds within the food category. In-depth investigation is ongoing to determine anti-biofilm properties against various micro-organisms problematic in food and healthcare industries. Studies focused on both prevention of biofilm formation and post-formation disruption.

2Immdal Group
Strategic tierCoreTypeOthers
Description

Immcell is a family-owned nutraceutical company that forms an integral part of the Immdal Group, with innovation at the heart of all operations and focus on new-to-world plant-based technologies.

immcell.ie
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global ingredient solutions provider with plant-based proteins and specialty starches. Comparable B2B ingredient licensing/supply model serving food and beverage manufacturers.

TypeBroad incumbent
Description

Irish-headquartered global nutrition and ingredient company with plant-based protein and premix offerings. Comparable Irish B2B ingredient model serving food and supplement manufacturers.

TypeBroad incumbent
Description

Global leader in plant-based ingredients including pea protein (NUTRALYS) and other specialty proteins. Operates at vastly larger scale but addresses the same B2B functional protein market as Immcell.

TypeBroad incumbent
Description

Irish-headquartered B2B food ingredients and taste solutions giant. Strong geographic and customer overlap with Immcell's food industry focus, but at much larger scale across broader ingredient categories.

TypeDirect peer
Description

Canadian plant protein ingredient company that has developed canola/rapeseed proteins (Puratein, Supertein). Directly comparable to Immcell's rapeseed protein ingredient business in both feedstock and target B2B customers.

TypeBroad incumbent
Description

Global nutrition and agricultural processor with substantial plant protein ingredient business. Major potential competitor and/or licensing partner for functional food ingredients.

7AGT Food and Ingredients
TypeDirect peer
Description

Global supplier of pulse and plant protein ingredients to food manufacturers. Comparable B2B plant-protein ingredient model with similar customer base of food and beverage formulators.

TypeBroad incumbent
Description

Global agribusiness with extensive plant protein ingredient portfolio (e.g., Puris pea protein). Competes for the same B2B protein customers with vastly greater scale and R&D resources.

TypeEmerging player
Description

Canadian biotech developing anti-biofilm technologies for human and animal health applications. Directly comparable to Immcell's Natural Biofilm Inhibitor program in technology and end markets.

10BioFilm Control
TypeEmerging player
Description

French biotech focused on anti-biofilm enzyme-based solutions for healthcare and food safety. Closest emerging technology peer to Immcell's biofilm-disruption approach.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immcell Ltd

Plant-based Nutraceutical Ingredientsimmcell.ie

Immcell Limited is an Ireland-based, family-owned B2B company within the Immdal Group that develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions, including Rapeseed Protein, B-NUC™ Beta Inosine, and a Natural Biofilm Inhibitor, to food and pharmaceutical industry partners.

What Immcell Ltd does

Immcell Limited is an Ireland-based, family-owned B2B ingredient and pharmaceutical technology company operating within the Immdal Group, headquartered in Swords, Co. Dublin. The company develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions through two operating divisions: Immcell Nutra, which supplies functional food ingredients such as Rapeseed Protein (a PDCAAS-1 plant protein derived from rapeseed meal, a by-product of cold press oil extraction) and B-NUC™ (a trademarked high-purity beta polymorph of inosine positioned for immune system modulation); and Immcell Pharma, which is developing a Natural Biofilm Inhibitor in collaboration with Technological University Dublin, targeting biofilm prevention and disruption across food manufacturing and healthcare applications.

The underlying technology relies on proprietary natural-compound formulations, GMP manufacturing standards, and academic co-development rather than in-house AI-driven discovery. Products are positioned for integration into B2B partners' own brands and formulations, with applications spanning nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, bakery, capsules, beverages, medical devices, and food preservation. Manufacturing is conducted to GMP standards and is accompanied by a consolidated clinical development network for the pharmaceutical product line.

Immcell monetizes primarily through B2B licensing and distribution agreements with food and pharmaceutical industry partners, complemented by direct R&D sample sales (for example, Rapeseed Protein priced at €30 per 10 grams) via an online shop to facilitate partner evaluation. Go-to-market is sales-led, conducted through the corporate website, newsletter, and direct contact (phone and email), with no consumer-facing retail channel. The company's stated target markets are global, although its identified served geography is currently EMEA, and no customer logos, revenue figures, or funding rounds are publicly disclosed.

Immcell Ltd firmographics

Firmographics
Name
Immcell Ltd
Legal name
Immcell Limited
Website
https://immcell.ie
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Immcell Limited is an Ireland-based, family-owned B2B company within the Immdal Group that develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions, including Rapeseed Protein, B-NUC™ Beta Inosine, and a Natural Biofilm Inhibitor, to food and pharmaceutical industry partners.
Ownership category
akta.pro rank

Immcell Ltd industry classification

Industry
Product category
Plant-based Nutraceutical Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833), Miscellaneous Food Preparations & Kindred Products (2090)
akta.pro industry
PRIMARYCRADAOAM
Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYAFAKAJAD
Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium)
Agriculture & Food Production/Food Processing & Manufacturing/Specialty & Functional Foods Manufacturing (Organic, Fortified, Medical Foods)

Keywords

  • Plant-based protein ingredients
  • Functional food ingredients
  • Nutraceutical ingredients
  • Pharmaceutical technology licensing
  • Anti-biofilm technology

Where Immcell Ltd is headquartered

Location

Headquarters

HQ city
Swords
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Immcell Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. B2B Product Licensing: Licensing innovative plant-based technologies and ingredients to B2B partners in the food and pharmaceutical industries for integration into their product formulations and brands.
  2. Sample Product Sales: Direct sales of product samples (Rapeseed Protein at €30.00 for 10 grams) for R&D purposes to potential B2B partners evaluating ingredients for incorporation into their products.
  3. Technology Solutions Licensing: Licensing of pharmaceutical technology solutions including the Natural Biofilm Inhibitor technology to healthcare and pharmaceutical companies.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRapeseed Protein Sample (10g)
OtherMulti-year contractB-NUC™ (Beta Inosine) - Commercial Quantities

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Immcell Ltd product offering

Product offering

Core offering

Immcell develops and supplies proprietary plant-based nutraceutical ingredients and pharmaceutical technology solutions to B2B customers in the food and pharmaceutical industries. Its commercial portfolio centers on Rapeseed Protein (a plant-based protein from rapeseed meal), B-NUC™ Beta Inosine (an immune-modulating functional ingredient), and the Natural Biofilm Inhibitor (anti-biofilm technology developed with Technological University Dublin), all manufactured to GMP standards and delivered primarily via licensing and ingredient supply partnerships.

Product overview

Immcell operates through two main divisions: Immcell Nutra and Immcell Pharma. Immcell Nutra offers functional food ingredients including Rapeseed Protein (plant-based protein with complete amino acid profile for nutritional applications) and B-NUC™ (Beta Inosine), an immune-modulating functional ingredient. Immcell Pharma focuses on technology-based pharmaceutical solutions, including the Natural Biofilm Inhibitor developed in collaboration with Technological University Dublin. The company manufactures products to GMP standards for B2B distribution and licensing.

Differentiator

Problem solved

Functional benefit

Brands

  • B-NUC™ (Beta Inosine): Innovative functional food ingredient - a high purity beta polymorph of inosine that modulates the immune system.
  • Rapeseed Protein
  • Natural Biofilm Inhibitor

Products and services

  • Rapeseed Protein (RSP) Plant-based protein ingredient produced from rapeseed meal (a by-product of cold press rapeseed oil extraction), with a complete essential amino acid profile, non-GMO and Irish-sourced credentials, dairy and lactose free, and a PDCAAS-1 rating. Designed for B2B integration into nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, and bakery products by food and beverage manufacturers.
  • B-NUC™ (Beta Inosine) Trademarked high-purity beta polymorph of inosine developed by Immcell as a functional food ingredient that modulates the immune system, supporting innate and adaptive immunity, cognition, energy generation, nerve cell and brain health, and heart health. Suitable for capsules, gels, bars, protein powders, yoghurts, beverages, and smoothies across all age groups, with particular relevance for the ageing population; offered for B2B licensing and supply.
  • Natural Biofilm Inhibitor Anti-biofilm pharmaceutical technology developed with Technological University Dublin (TUD) that investigates anti-biofilm activity of specific compounds, targeting both prevention of biofilm formation and post-formation disruption. Intended for B2B licensing to medical device manufacturers (catheters, prosthetics), food and beverage manufacturing plants, and fruit and vegetable preservation applications in the pharmaceutical and healthcare sectors.

Quantifiable outcome

  • Plant-based food sales grew 5 times faster than overall retail food sales (11% v 2%)
  • +2 more outcomes

Companies that use Immcell Ltd

Customer profile

Segments2 records

Ideal customer profiles2 records

Immcell Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Immcell Ltd partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Technological University Dublin (TUD)coreStrategic or Co-development PartnerOngoing research collaboration investigating anti-biofilm activity of specific compounds within the food category. In-depth investigation is ongoing to determine anti-biofilm properties against various micro-organisms problematic in food and healthcare industries. Studies focused on both prevention of biofilm formation and post-formation disruption.
  • Immdal GroupcoreOthersImmcell is a family-owned nutraceutical company that forms an integral part of the Immdal Group, with innovation at the heart of all operations and focus on new-to-world plant-based technologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Immcell Ltd competitors and assessment

Company assessment

Broad incumbents

  • Ingredion: Global ingredient solutions provider with plant-based proteins and specialty starches. Comparable B2B ingredient licensing/supply model serving food and beverage manufacturers.
  • Glanbia Nutritionals: Irish-headquartered global nutrition and ingredient company with plant-based protein and premix offerings. Comparable Irish B2B ingredient model serving food and supplement manufacturers.
  • Roquette: Global leader in plant-based ingredients including pea protein (NUTRALYS) and other specialty proteins. Operates at vastly larger scale but addresses the same B2B functional protein market as Immcell.
  • Kerry Group: Irish-headquartered B2B food ingredients and taste solutions giant. Strong geographic and customer overlap with Immcell's food industry focus, but at much larger scale across broader ingredient categories.
  • ADM (Archer Daniels Midland): Global nutrition and agricultural processor with substantial plant protein ingredient business. Major potential competitor and/or licensing partner for functional food ingredients.
  • Cargill: Global agribusiness with extensive plant protein ingredient portfolio (e.g., Puris pea protein). Competes for the same B2B protein customers with vastly greater scale and R&D resources.

Direct peers

  • Burcon NutraScience: Canadian plant protein ingredient company that has developed canola/rapeseed proteins (Puratein, Supertein). Directly comparable to Immcell's rapeseed protein ingredient business in both feedstock and target B2B customers.
  • AGT Food and Ingredients: Global supplier of pulse and plant protein ingredients to food manufacturers. Comparable B2B plant-protein ingredient model with similar customer base of food and beverage formulators.

Emerging players

  • Kane Biotech: Canadian biotech developing anti-biofilm technologies for human and animal health applications. Directly comparable to Immcell's Natural Biofilm Inhibitor program in technology and end markets.
  • BioFilm Control: French biotech focused on anti-biofilm enzyme-based solutions for healthcare and food safety. Closest emerging technology peer to Immcell's biofilm-disruption approach.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Immcell Ltd social profiles

Digital presence

Immcell Ltd compliance and trust

Trust signal

Compliance1 record

Immcell Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immcell Ltd leadership team

Management profile

Number of profiles

Immcell Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immcell Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immcell Ltd

What does Immcell Ltd do?

Immcell develops and supplies proprietary plant-based nutraceutical ingredients and pharmaceutical technology solutions to B2B customers in the food and pharmaceutical industries. Its commercial portfolio centers on Rapeseed Protein (a plant-based protein from rapeseed meal), B-NUC™ Beta Inosine (an immune-modulating functional ingredient), and the Natural Biofilm Inhibitor (anti-biofilm technology developed with Technological University Dublin), all manufactured to GMP standards and delivered primarily via licensing and ingredient supply partnerships.

Is Immcell Ltd a public or private company?

Immcell Ltd is a private company. It is classified as family owned and is currently operating.

When was Immcell Ltd founded?

Immcell Ltd was founded in 2011. It employs 1 to 10 people.

Where is Immcell Ltd based?

Immcell Ltd is headquartered in Swords, Ireland, in the Europe region.

How does Immcell Ltd make money?

Three revenue lines are on record. B2B Product Licensing is the primary driver. The others are sample Product Sales and technology Solutions Licensing.

Who are Immcell Ltd's main competitors?

Broad incumbents on record are Ingredion, Glanbia Nutritionals, Roquette, Kerry Group, ADM (Archer Daniels Midland) and Cargill. Direct peers are Burcon NutraScience and AGT Food and Ingredients. Emerging players are Kane Biotech and BioFilm Control.

Does Immcell Ltd have an API?

No public API is recorded for Immcell Ltd.

What industry is Immcell Ltd in?

Immcell Ltd's product category is Plant-based Nutraceutical Ingredients. Its primary akta.pro industry code is CRADAOAM, Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes), with a secondary code of CRADAOAF, Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales